Low dose oral desmopressin for nocturnal polyuria in patients with benign prostatic hyperplasia: a double-blind, placebo controlled, randomized study

What Was Tested

This randomized controlled trial paper looks at Vasopressin and Desmopressin in the context of hyperparathyroidism.

Who Took Part

By PubMed's age tags, the people studied were older adults and people over 80, men only.

Eligible patients with benign prostatic hyperplasia older than 65 years with nocturia, nocturnal polyuria and International Prostate Symptom Score 14 or greater were included in the study.

Patients were required to visit the outpatient clinic from the first visit, and after 1, 3, 6 and 12 months of treatment.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Because people in this Vasopressin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Vasopressin.

The comparison arm used a placebo, so changes seen with Vasopressin could be set against what happens without it.

Patients maintained flow volume charts and used diaries to record voiding data throughout the study.

During followup urinalysis, urine sodium, urine osmolality, serum electrolytes, prostate specific antigen, International Prostate Symptom Score, quality of life, transrectal ultrasonography of prostate, uroflowmetry and post-void residual urine volume were performed at each visit.

What Was Measured

The subject headings attached to it are Antidiuretic Agents, Deamino Arginine Vasopressin, Polyuria and Prostatic Hyperplasia.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vasopressin and Desmopressin in people with hyperparathyroidism.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2011 (The Journal of urology), a journal based in United States.

More context: the Vasopressin compound page and the Desmopressin compound page, Hyperparathyroidism research.